ClearPoint Neuro (CLPT): MAK Capital group discloses 7.8% ownership in 13G/A
Rhea-AI Filing Summary
ClearPoint Neuro, Inc. has a Schedule 13G/A filed by MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman reporting their ownership of the company’s common stock. The reporting persons collectively beneficially own 2,375,861 shares of common stock, representing 7.8% of the outstanding class as of June 30, 2026, based on 30,504,227 shares outstanding as of July 27, 2026.
The reporting persons report 0 shares with sole voting or dispositive power and 2,375,861 shares with shared voting and shared dispositive power. The amendment is signed by Michael A. Kaufman in his capacity as managing member and individual reporting person.
Positive
- None.
Negative
- None.
Key Figures
Shares beneficially owned: 2,375,861 shares
Percent of class: 7.8%
Shares outstanding: 30,504,227 shares
+2 more
5 metrics
Shares beneficially owned
2,375,861 shares
Common Stock beneficially owned by the reporting persons as of 06/30/2026
Percent of class
7.8%
Portion of ClearPoint Neuro common stock beneficially owned by the reporting persons
Shares outstanding
30,504,227 shares
ClearPoint Neuro common stock outstanding as of July 27, 2026, per Form 10-Q
Shared voting power
2,375,861 shares
Number of shares over which the reporting persons have shared voting power
Shared dispositive power
2,375,861 shares
Number of shares over which the reporting persons have shared dispositive power
Key Terms
beneficially owned, shared voting power, shared dispositive power, Schedule 13G/A, +1 more
5 terms
beneficially owned financial
"The calculation is based upon 2,375,861 shares of Common Stock beneficially owned as of 06/30/2026"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Schedule 13G/A regulatory
"This /A is being filed by: i. MAK Capital Fund LP ("MAK Fund")"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
percent of class financial
"Percent of class: 7.8%"
Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What ownership stake in CLPT does MAK Capital report in this Schedule 13G/A?
The reporting persons collectively beneficially own 2,375,861 shares of ClearPoint Neuro (CLPT) common stock, representing 7.8% of the outstanding shares based on 30,504,227 shares outstanding as of July 27, 2026.
Who are the reporting persons in the ClearPoint Neuro (CLPT) Schedule 13G/A?
The Schedule 13G/A is filed jointly by MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman, who together report beneficial ownership and shared voting and dispositive power over ClearPoint Neuro common stock.
What type of ClearPoint Neuro (CLPT) securities are covered in this Schedule 13G/A?
The filing covers Common Stock, $0.01 par value per share of ClearPoint Neuro, Inc., identified by CUSIP 18507C103, with 2,375,861 shares reported as beneficially owned by the reporting persons.